IL280340B - נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס - Google Patents

נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס

Info

Publication number
IL280340B
IL280340B IL280340A IL28034021A IL280340B IL 280340 B IL280340 B IL 280340B IL 280340 A IL280340 A IL 280340A IL 28034021 A IL28034021 A IL 28034021A IL 280340 B IL280340 B IL 280340B
Authority
IL
Israel
Prior art keywords
peptides
antibodies
prevention
combinations
treatment
Prior art date
Application number
IL280340A
Other languages
English (en)
Inventor
Shulman Ziv
David Mazor Roei
Stoler-Barak Liat
ASAF Lihee
Nathan Nachum
KAGAN BEN TIKVA Sharon
Original Assignee
Yeda Res & Dev
Shulman Ziv
David Mazor Roei
Liat Stoler Barak
ASAF Lihee
Nathan Nachum
KAGAN BEN TIKVA Sharon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev, Shulman Ziv, David Mazor Roei, Liat Stoler Barak, ASAF Lihee, Nathan Nachum, KAGAN BEN TIKVA Sharon filed Critical Yeda Res & Dev
Priority to IL280340A priority Critical patent/IL280340B/he
Priority to PCT/IL2022/050088 priority patent/WO2022157774A1/en
Publication of IL280340B publication Critical patent/IL280340B/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1002—Coronaviridae
    • C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
IL280340A 2021-01-21 2021-01-21 נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס IL280340B (he)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IL280340A IL280340B (he) 2021-01-21 2021-01-21 נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס
PCT/IL2022/050088 WO2022157774A1 (en) 2021-01-21 2022-01-20 Antibodies, peptides and combinations of same for the treatment or prevention of coronavirus infection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL280340A IL280340B (he) 2021-01-21 2021-01-21 נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס

Publications (1)

Publication Number Publication Date
IL280340B true IL280340B (he) 2022-04-01

Family

ID=80446372

Family Applications (1)

Application Number Title Priority Date Filing Date
IL280340A IL280340B (he) 2021-01-21 2021-01-21 נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס

Country Status (2)

Country Link
IL (1) IL280340B (he)
WO (1) WO2022157774A1 (he)

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
EP1012275A1 (en) 1997-01-31 2000-06-28 University Of Rochester Chimeric antibody fusion proteins for the recruitment and stimulation of an antitumor immune response
US10960070B2 (en) * 2016-10-25 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Prefusion coronavirus spike proteins and their use
CN111337672B (zh) * 2020-05-18 2020-09-08 博奥赛斯（天津）生物科技有限公司 一种新型冠状病毒IgG抗体的酶联免疫法检测试剂盒
CN111961138B (zh) * 2020-10-20 2021-03-30 苏州茂行生物科技有限公司 疫苗融合蛋白

Also Published As

Publication number Publication date
WO2022157774A1 (en) 2022-07-28

Similar Documents

Publication Publication Date Title
EP3980400A4 (en) PEPTIDOMIMETICS FOR THE TREATMENT OF CORONAVIRUS AND PICORNAVIRUS INFECTIONS
PH12021550542A1 (en) Multivalent pneumococcal vaccines
AU2020342649B2 (en) Compositions and methods for the treatment of viral infections
PL4157272T3 (pl) Remdesiwir do leczenia zakażeń wirusowych
EP4414385A3 (en) Polyomavirus neutralizing antibodies
EP3745967A4 (en) DEVICES AND METHODS FOR TREATMENT OF BLOCKED BLOOD VESSELS
WO2019106578A3 (en) Polyomavirus neutralizing antibodies
MX2021002909A (es) Vacunas de proteinas de fusion neumococicas.
MX2024002779A (es) Vacunas neumocócicas multivalentes.
EP4048406A4 (en) COMBINATION THERAPY FOR THE TREATMENT OF SOLID AND HEMATOLOGICAL MALIGNANT TUMORS
WO2023122260A3 (en) Inhibitors of sars-cov-2
SG11202103103TA (en) Gdsl lipase, genetically-engineered bacteria and application thereof
ZA202211706B (en) Medicine/agent for the treatment of coronavirus, retroviral infections and hepatitis c
EP3955927A4 (en) COMPOSITIONS AND METHODS FOR TREATING, AMOUNTING AND PREVENTING H. PYLORI INFECTIONS
IL288478A (he) שיטות, תכשירים ומכשירים לטיפול במצבים נוירואינפלמטוריים
IL280340B (he) נוגדנים, פפטידים וצירופים שלהם לטיפול ומניעה של זיהומי קורונה וירוס
EP4121038A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CORONAVIRUS INFECTION AND RESPIRATORY COMPROMISE
EP3747451A4 (en) PROPHYLACTIC AND / OR THERAPEUTIC AGENT FOR PNEUMOCOCCIC INFECTION
HK40109014A (en) Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
WO2010105191A3 (en) Antimicrobial compositions and methods of use therefore
MX2022015279A (es) Diagnostico, prevencion y tratamiento de la infeccion por coronavirus.
HK1206594A1 (en) Materials and methods for prevention and treatment of viral infections
IL308042A (he) נוגדנים לטיפול ומניעה של covid-19 ושל וריאנטים מתעוררים
HK40101696A (zh) 肾毒素诱发的肾损伤的治疗和预防
HK40095975A (zh) 用於治疗和预防冠状病毒感染的抗tmem106b抗体